amuvatinib

Amuvatinib (MP470) is an orally bioavailable synthetic carbothioamide with potential antineoplastic activity.

Amuvatinib hydrochloride (MP470 hydrochloride) is an orally administred multi-targeted tyrosine kinase inhibitor that exhibits strong efficacy against mutant forms of c-Kit, PDGFRα, Flt3, c-Met, and c-Ret, while also acting as a suppressor of DNA repair by inhibiting the RAD51 protein, which is crucial for repairing DNA damage[1][2][3]. This dual mechanism contributes to its antineoplastic activity[4].